PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Go online to PeerView.com/FSN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. After many years of slow progress, the treatment arsenal has finally expanded and more hope is on the horizon for patients with small cell lung cancer (SCLC). Notable advances such as chemo-immunotherapy in the first-line setting and lurbinectedin in the second-line setting have now become guideline-recommended standards of care and propelled the treatment of SCLC forward. Further research efforts are focused on understanding the underlying biology and potential subtypes of SCLC, what biomarkers may be useful in refining treatment selection, and evaluation of novel therapeutic options and rational combinations. In this PeerView Live Candid Conversations & Clinical Consults symposium, based on a recent live symposium, leading experts weave together the latest evidence on standard-of-care therapies and the evolving data on new/emerging approaches to provide a big-picture overview of the present and future management of SCLC and how to accelerate further progress in this challenging disease. These discussions are framed with illustrative patient cases to highlight evidence-based strategies to improve care and outcomes in SCLC. Upon completion of this activity, participants should be better able to: Analyze the role and use of current and emerging therapies for SCLC and the evidence supporting their use; Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, rapid initiation of therapy, and optimal care throughout the disease continuum for each patient with SCLC; Incorporate current standard-of-care therapies into individualized treatment plans for eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC to facilitate progress and improve outcomes

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Go online to PeerView.com/DWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. First- and second-generation Bruton tyrosine kinase (BTK) inhibitors have transformed the standard of care in many different chronic lymphocytic leukemia (CLL) settings—from treatment-naïve to relapsed disease, as well as in high-risk settings—but are you prepared to fully integrate established and emerging BTKi options into clinical practice, including in the context of community-based care? Find out by viewing this activity, which highlights the clinical decision-making of an academic and a community specialist. Throughout, the panelists will use a series of real-world cases to demonstrate the practicalities of using modern BTKi therapy, provide guidance on the use of next-generation agents, and offer a strong grounding for updated AE management protocols that can ensure safe delivery of care. Upon completion of this activity, participants should be better able to: Summarize evidence from pivotal clinical trials and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Recommend personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Select individualized, sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Manage adverse events associated with the use of novel targeted approaches with BTK inhibitors in the CLL setting.

Go online to PeerView.com/KYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The visual guide to hypertrophic cardiomyopathy (HCM) you’ve been waiting for is here! In contemporary care, patients with HCM have options that may reduce the need for invasive treatments. This engaging presentation is perfect for both visual and auditory learners to update their understanding of HCM, tune in to the signs and symptoms that should raise suspicion, and learn best practices to confirm a diagnosis of HCM. Once diagnosed, you’ll need to know the latest data on cardiac myosin inhibitors and practical guidance for integrating them into patient care. This activity delivers on all of the above—set aside some time and click “play” today! Upon completion of this activity, participants should be better able to: Recognize clinical characteristics and/or features that suggest the presence of HCM; Accurately diagnose patients with suspected HCM using expert guidance and the latest recommendations to promote early identification and treatment; and Personalize the medical treatment of HCM using strategies with disease-modifying potential based upon the latest efficacy and safety evidence and consistent with current prescribing and monitoring recommendations to ensure long-term patient safety and improve clinical outcomes.

Go online to PeerView.com/BPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While homozygous familial hypercholesterolemia (HoFH) is associated with development of atherosclerotic cardiovascular disease in childhood, early recognition and treatment of this inherited disease can improve outcomes for patients. In this animated activity provided by PeerView in collaboration with the Family Heart Foundation, a cardiologist describes the impact of this rare disease on patients and their families, presents strategies for recognizing signs and symptoms of HoFH, and reviews guidelines for genetic screening and referral of patients and their families to appropriate experts and resources for support. Additionally, two patients share their experiences of living with HoFH. Upon completion of this activity, participants should be better able to: Describe the consequences of undiagnosed and untreated HoFH from the patient’s perspective; Distinguish hallmark signs, symptoms, and family history differentiating HoFH from other disorders; and Employ current guidelines and support resources to direct patients with suspected HoFH to appropriately qualified care providers.

Go online to PeerView.com/YNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuances related to modern treatment of patients with desmoid tumors. This educational program comprises a series of short, focused educational modules that hone in on some of the key questions in the diagnosis and treatment of desmoid tumors. Experts provide an update on the evolving evidence base for new and emerging therapies, and offer practical, case-based guidance for the multidisciplinary care team to help facilitate the application of recent advances to practice with the goal of improving patient care and outcomes. Patient perspectives and experiences are also integrated into the activity to highlight the importance of their education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Characterize the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of desmoid tumors; Implement validated strategies that harness multidisciplinary team-based approaches for rapid recognition and accurate diagnosis of desmoid tumors; and Incorporate novel therapeutic approaches, including novel gamma-secretase inhibitors, into practice in the management of patients with desmoid tumors, taking into account the latest evidence, recommendations, and patient needs and preferences.

Go online to PeerView.com/BNB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert on homozygous familial hypercholesterolemia (HoFH) discusses the latest data for novel lipid-lowering therapies and offers strategies for individualizing treatment regimens to improve outcomes for patients with HoFH. Upon completion of this activity, participants should be better able to: Apply standards of care to initiate and escalate lipid-lowering therapies in patients with HoFH; Distinguish the therapeutic characteristics of recently approved HoFH therapies according to their mechanisms of action; and Evaluate the benefits and limitations of approved HoFH therapies to individualize patient care.

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Go online to PeerView.com/XMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Psoriasis, a chronic inflammatory disease that affects up to 1 in 20 people worldwide, can drastically impact a patient's quality of life and health. The number of therapies for patients with moderate-to-severe psoriasis has grown steadily over the past 2 decades. Biologic immunotherapies have been the primary agents to gain approval, while small-molecule therapies have lagged in development. Deucravacitinib is a newly approved oral small molecule that inhibits the activity of TYK2, a member of the JAK family. Deucravacitinib allosterically inhibits TYK2 activity by binding to the regulatory domain rather than the catalytic domain. Binding in this way gives deucravacitinib greater specificity for TYK2 versus the closely related JAK1/2/3. Deucravacitinib has demonstrated safety and efficacy in moderate-to-severe chronic plaque psoriasis in two phase 3 pivotal trials (POETYK PSO-1 and PSO-2). Psoriasis Area Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1 response rates were significantly higher with deucravacitinib versus placebo or apremilast. In this activity, based on a recent live symposium, expert faculty discuss the clinical implications of targeting TYK2 in psoriasis, as well as strategies to identify patients for whom inhibition of TYK2 would be an appropriate treatment option based on available data. In addition, the faculty delve into the importance of shared decision-making in formulating personalized management plans for patients with psoriasis. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of moderate-to-severe psoriasis as it relates to selective targeting of TYK2; Identify patients with psoriasis for whom inhibition of TYK2 would be an appropriate treatment option based on available efficacy and safety data and practice guidelines; and Develop personalized management plans for patients with psoriasis using principles and tools of shared decision-making, empowering patients to participate in treatment decisions and remain adherent to therapies

Go online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel of experts in GI malignancies presents evidence-based guidance on modern diagnostic protocols and the personalized treatment of fusion-driven cancers. With relevant cases framing the discussion, the panel provides foundational knowledge on tumor-agnostic genomic alterations, updates on genomic testing techniques sensitive enough to capture rare alterations, and strategies for integrating targeted agents into treatment plans. Upon completion of this activity, participants should be better able to: Explain current guidelines and evidence related to molecular testing and targeted therapeutics, enabling timely diagnosis, and treatment of gene fusion–driven GI cancers; Implement collaborative, multidisciplinary genomic testing protocols designed to capture less common but actionable molecular alterations in metastatic or locally advanced GI cancers; and Construct safe, individualized treatment plans for patients with advanced GI cancers who present with uncommon genomic alterations